EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Drug–drug interactions in the management of non-tuberculous mycobacterial infections

Kazuaki Takeda, Takahiro Takazono, Hiroshi Mukae

Frontiers in Microbiology · 05.09.2024 · 15

DOI: 10.3389/fmicb.2024.1468383 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Microbiology, online erschienen am 05.09.2024. Verfasst von Kazuaki Takeda und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Non-tuberculous mycobacterial pulmonary disease (NTM-PD) is a refractory chronic respiratory infectious disease and its prevalence is increasing globally. The standard treatment regimen for NTM-PD involves long-term multidrug therapy including macrolides. The incidence of adverse events is high given the advanced age of many NTM-PD patients. In addition, drug–drug interactions under coexisting conditions add additional complexity. Despite guidelines advocating multidrug therapy for NTM-PD, low adherence rates probably owing to the relatively frequent adverse events and drug interactions. An appropriate treatment regimen can improve the bacteriological response rates, reduce the development of macrolide resistance, and mitigate adverse events. Of particular concern are the interactions arising from new complications that develop with NTM-PD. Notably, chronic pulmonary aspergillosis occasionally co-infects NTM-PD, which can lead to poor prognosis. The primary therapeutic modality for chronic pulmonary aspergillosis is the azoles. However, the interaction with rifamycin is problematic, making it challenging to continue standard treatment for NTM-PD and requiring drug adjustments. The implications of rifamycin extend beyond chronic pulmonary aspergillosis, impacting various other diseases such as those requiring immunosuppressive agents and AIDS patients requiring antiretroviral therapy. Hence, a comprehensive consideration of drug interactions is imperative for the initiation of NTM-PD treatment. This mini-review focuses on drug–drug interactions in a multidrug regimen for NTM-PD and discusses the essential points to be considered in the treatment of NTM.

Schlagwörter

Stichwörter der Autor:innen

adverse eventantiretroviral therapychronic pulmonary aspergillosisdrug interactionnon-tuberculous mycobacterial infection

Autor:innen und Institutionen

  • Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.
  • Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
  • Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Zitieren

APA

Takeda, K., Takazono, T., & Mukae, H. (2024). Drug–drug interactions in the management of non-tuberculous mycobacterial infections. Frontiers in Microbiology, 15. https://doi.org/10.3389/fmicb.2024.1468383

Vancouver

Takeda K, Takazono T, Mukae H. Drug–drug interactions in the management of non-tuberculous mycobacterial infections. Frontiers in Microbiology. 2024;15. doi:10.3389/fmicb.2024.1468383

BibTeX
@article{Takeda2024,
  author = {Takeda, Kazuaki and Takazono, Takahiro and Mukae, Hiroshi},
  title = {Drug–drug interactions in the management of non-tuberculous mycobacterial infections},
  journal = {Frontiers in Microbiology},
  year = {2024},
  volume = {15},
  doi = {10.3389/fmicb.2024.1468383}
}
Kostenlos starten →